Margaret Irene Gores, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 505 N Main Ave, Aztec, NM 87410 Phone: 505-334-9616 Fax: 505-334-7343 |
Physical Therapy & Sports Medicine Of Northern New Mexico, Inc. Physical Therapist Medicare: Medicare Enrolled Practice Location: 505 N Main Ave, Aztec, NM 87410 Phone: 505-334-9616 Fax: 505-334-7343 |
Gordon Henriksen Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1607 W Aztec Blvd, Aztec, NM 87410 Phone: 505-334-3695 |
Matthew Vidal Fernandez, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 505 N Main Ave, Aztec, NM 87410 Phone: 505-334-9616 |
Mr. Sid Mosiman, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 604 S Rio Grande Ave, Aztec, NM 87410 Phone: 505-334-9616 Fax: 505-334-7343 |
News Archive
Three groups in Iraq - including about 35 Iraqis who allegedly contracted HIV through contaminated blood products in the 1980s - have filed a civil lawsuit against the country's Ministry of Health and two companies that sold blood products, the New York Times reports.
Researchers at UT Southwestern Medical Center have identified in mice a compound that liberates cholesterol that has inappropriately accumulated to excessive levels inside cells.
A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes.
On Monday, President Barack Obama joined with AARP chief Barry Rand to announce "an agreement among pharmaceutical companies to cut prescription drug costs for seniors - and inject some energy into his efforts at comprehensive health care reform," Politico reports. Obama said the companies' goal is to "to reduce the punishing inflation in health care while improving patient care."
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
› Verified 4 days ago